Functional genomics can help deconvolute the link between genotype and phenotype in disease, revealing new drug targets and ...

CRISPR-Cas systems have been exploited for targeted genome editing. Applying the CRISPR-Cas9 system to edit high GC content genomes has been challenging due to its high off-target activity.

By 2025, innovations such as lab-on-a-chip technology, automation, and CRISPR-Cas9 gene editing are expected to enhance ...

Intellia Therapeutics, Inc. NTLA lost 21.6% in a week as investors were disappointed with the company’s plans for portfolio ...

CRISPR screening libraries are collections of carefully designed single-guide RNAs (sgRNAs) that allow researchers to ...

The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...

The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...

A groundbreaking study led by the Mayo Clinic Comprehensive Cancer Center has significantly deepened our understanding of ...

Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center have significantly advanced the understanding of genetic alterations in the ...

Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.